Top Page
Artelo Biosciences
(NASDAQ:ARTL)
Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)
Artelo Biosciences Business Overview & Revenue Model
Artelo Biosciences Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.54M | -10.11M | -9.93M | -10.08M | -7.44M |
| Net Income | -12.88M | -9.83M | -9.29M | -10.08M | -7.44M |
Balance Sheet | |||||
| Total Assets | 2.80M | 4.70M | 13.04M | 20.42M | 12.63M |
| Cash, Cash Equivalents and Short-Term Investments | 600.00K | 2.34M | 10.43M | 17.53M | 10.06M |
| Total Debt | 693.00K | 104.00K | 23.00K | 63.00K | 95.00K |
| Total Liabilities | 4.07M | 1.84M | 1.29M | 1.02M | 593.00K |
| Stockholders Equity | -1.27M | 2.86M | 11.75M | 19.40M | 12.04M |
Cash Flow | |||||
| Free Cash Flow | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Operating Cash Flow | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Investing Cash Flow | -62.00K | 7.77M | 3.51M | 2.96M | -3.44M |
| Financing Cash Flow | 6.87M | 112.00K | 567.00K | 0.00 | 14.11M |
Artelo Biosciences Technical Analysis
Artelo Biosciences Risk Analysis
Artelo Biosciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $7.09M | -0.04 | -166.96% | ― | ― | 83.25% | |
42 Neutral | $3.13M | -0.02 | -262.78% | ― | ― | 79.45% | |
41 Neutral | $2.42M | -0.07 | -436.14% | ― | ― | -22.52% | |
41 Neutral | $625.72K | -0.02 | -60.37% | ― | -100.00% | 86.75% | |
41 Neutral | $4.71M | -0.07 | -317.98% | ― | ― | 34.57% |
Artelo Biosciences Corporate Events
On January 30, 2026, Artelo Biosciences, Inc. entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5, giving the company the right, but not the obligation, to sell up to $25 million of its common stock to Square Gate, with the capacity to increase the facility by an additional $25 million once the initial amount is fully used, in exchange for issuing 292,398 commitment shares valued at $500,000 and covering up to $35,000 of Square Gate’s due diligence and legal costs. The deal, which runs through January 30, 2029 unless earlier terminated, is structured as a private placement exempt from SEC registration and includes detailed volume, pricing, ownership, and exchange-cap limits on drawdowns, along with a Registration Rights Agreement obligating Artelo to register the resale of the shares, providing the company with a flexible, multiyear equity financing source while limiting immediate dilution and concentration of ownership for existing shareholders.
The most recent analyst rating on (ARTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
On February 2, 2026, Artelo Biosciences said it received a decision from a Nasdaq Hearing Panel granting the company an exception to cure its listing deficiencies, provided it demonstrates by March 30, 2026 that it complies with the Nasdaq requirement to maintain at least $2.5 million in stockholders’ equity and discloses the transactions used to achieve and sustain that level. The exception follows a November 19, 2025 delisting determination for failure to meet the equity rule and a January 14, 2026 notice of non-compliance for not holding its 2025 annual meeting within the required timeframe; Artelo presented a remediation plan at a January 15, 2026 hearing, completed its adjourned annual meeting on January 30, 2026, and now faces a firm March 30, 2026 deadline to restore equity compliance to avoid potential delisting, creating continued uncertainty for shareholders and other stakeholders.
The most recent analyst rating on (ARTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
On January 30, 2026, Artelo Biosciences reconvened its previously adjourned Annual Meeting of Stockholders, achieving a quorum with approximately 50.4% of outstanding common shares represented. Shareholders re-elected Douglas Blayney, M.D., and Connie Matsui as Class II directors to serve until the 2028 annual meeting, approved on an advisory basis the executive compensation package for the company’s named executive officers, and ratified Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, thereby confirming support for current board composition, pay practices, and audit oversight.
The most recent analyst rating on (ARTL) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Artelo Biosciences convened but then adjourned its 2025 annual meeting of stockholders on December 31, 2025 without conducting any business due to a lack of quorum, and plans to reconvene the meeting on January 30, 2026 to allow more time for shareholders to vote on existing proposals and the ratification of its independent auditor for the 2026 fiscal year. After notifying Nasdaq that the annual meeting had been adjourned, the company received a notice on January 14, 2026 stating it was not in compliance with Nasdaq’s requirement to hold an annual meeting within one year of fiscal year-end, which may serve as an additional basis for delisting alongside its previously disclosed shortfall in minimum stockholders’ equity; while the notice does not immediately affect trading of its shares, the company has presented a plan to regain compliance to a Nasdaq hearing panel, though there is no assurance its efforts will succeed.
The most recent analyst rating on (ARTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
On December 31, 2025, Artelo Biosciences, Inc. convened but immediately adjourned its 2025 annual meeting of stockholders without conducting any business because it lacked a quorum of votes. The annual meeting is now scheduled to reconvene virtually on January 30, 2026, with the same record date of December 10, 2025, and previously submitted proxies still valid unless revoked. The company also plans to add a new proposal for shareholders to ratify the appointment of Malone Bailey LLP as independent auditor for the fiscal year ending December 31, 2026, while otherwise keeping the existing slate of proposals unchanged, a procedural step that may be important for governance continuity and auditor oversight but does not alter the company’s operational outlook.
The most recent analyst rating on (ARTL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
On November 19, 2025, Artelo Biosciences received a delist determination letter from Nasdaq due to non-compliance with Listing Rule 5550(b)(1), which requires maintaining stockholders’ equity of at least $2,500,000. Despite submitting plans to regain compliance, the company failed to raise the necessary capital. Artelo intends to appeal the decision to prevent delisting, allowing its stock to continue trading under the symbol ‘ARTL’ while the appeal is pending.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.